Symbols / ABBV
ABBV Chart
About
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 409.26B |
| Enterprise Value | 467.11B | Income | 4.19B | Sales | 61.16B |
| Book/sh | -1.85 | Cash/sh | 2.97 | Dividend Yield | 295.00% |
| Payout | 277.97% | Employees | 57000 | IPO | — |
| P/E | 98.54 | Forward P/E | 14.41 | PEG | — |
| P/S | 6.69 | P/B | -125.17 | P/C | — |
| EV/EBITDA | 15.97 | EV/Sales | 7.64 | Quick Ratio | 0.41 |
| Current Ratio | 0.67 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 2.35 | EPS next Y | 16.07 | EPS Growth | — |
| Revenue Growth | 10.00% | Earnings | 2026-05-01 | ROA | 9.81% |
| ROE | 62.25% | ROIC | — | Gross Margin | 71.62% |
| Oper. Margin | 34.11% | Profit Margin | 6.91% | Shs Outstand | 1.77B |
| Shs Float | 1.77B | Short Float | 1.11% | Short Ratio | 2.86 |
| Short Interest | — | 52W High | 244.81 | 52W Low | 164.39 |
| Beta | 0.33 | Avg Volume | 6.54M | Volume | 675.56K |
| Target Price | $248.29 | Recom | Buy | Prev Close | $228.51 |
| Price | $231.56 | Change | 1.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$248.29
Mean price target
2. Current target
$231.56
Latest analyst target
3. DCF / Fair value
$186.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$231.56
Low
$184.00
High
$299.00
Mean
$248.29
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | init | Barclays | — → Overweight | $275 |
| 2026-02-18 | main | Piper Sandler | Overweight → Overweight | $299 |
| 2026-02-05 | main | UBS | Neutral → Neutral | $230 |
| 2026-02-05 | main | Evercore ISI Group | Outperform → Outperform | $228 |
| 2026-02-05 | main | Morgan Stanley | Overweight → Overweight | $270 |
| 2026-01-27 | main | Citigroup | Neutral → Neutral | $230 |
| 2026-01-08 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-12-12 | main | Morgan Stanley | Overweight → Overweight | $269 |
| 2025-12-10 | up | HSBC | Hold → Buy | $265 |
| 2025-11-07 | main | UBS | Neutral → Neutral | $220 |
| 2025-11-05 | reit | Piper Sandler | Overweight → Overweight | $289 |
| 2025-11-03 | main | Citigroup | Neutral → Neutral | $235 |
| 2025-11-03 | main | JP Morgan | Overweight → Overweight | $260 |
| 2025-10-20 | main | Guggenheim | Buy → Buy | $242 |
| 2025-10-17 | reit | Raymond James | Outperform → Outperform | $250 |
| 2025-10-10 | main | Piper Sandler | Overweight → Overweight | $284 |
| 2025-10-09 | main | Cantor Fitzgerald | Overweight → Overweight | $250 |
| 2025-10-03 | main | B of A Securities | Neutral → Neutral | $251 |
| 2025-10-01 | down | HSBC | Buy → Hold | — |
| 2025-09-22 | main | Evercore ISI Group | Outperform → Outperform | $222 |
- AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance ue, 24 Feb 2026 14
- AbbVie’s $380M Illinois build to add 300 jobs, boost obesity drugs - Stock Titan Mon, 23 Feb 2026 16
- AbbVie Skids After An Unexpected Suspect Drove Its Beat - Investor's Business Daily Wed, 04 Feb 2026 08
- AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's Wed, 04 Feb 2026 08
- 3 Stocks to Buy and Hold for 2026 and Beyond - The Motley Fool hu, 19 Feb 2026 17
- Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more - Seeking Alpha Fri, 20 Feb 2026 13
- Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs - The Globe and Mail Mon, 23 Feb 2026 14
- UBS Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $260 - 富途牛牛 Wed, 25 Feb 2026 13
- AbbVie’s New CLL Regimen And US$380 Million Facilities Shift Narrative - simplywall.st Mon, 23 Feb 2026 19
- How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative - Yahoo Finance ue, 24 Feb 2026 19
- FDA approves first all-oral, fixed-duration option for CLL - Stock Titan Fri, 20 Feb 2026 07
- AbbVie stock slips despite Q4 beat (ABBV:NYSE) - Seeking Alpha Wed, 04 Feb 2026 08
- AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - Yahoo Finance Wed, 04 Feb 2026 08
- AbbVie wins FDA nod for leukemia therapy (update) (ABBV:NYSE) - Seeking Alpha Fri, 20 Feb 2026 16
- AbbVie Down Since Q4 Earnings Report: How to Play the Stock - Yahoo Finance ue, 17 Feb 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 36811 | — | — | Stock Award(Grant) at price 0.00 per share. | SALEKI-GERHARDT AZITA | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 82439 | — | — | Stock Award(Grant) at price 0.00 per share. | MICHAEL ROBERT A. | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 53749 | — | — | Stock Award(Grant) at price 0.00 per share. | STEWART JEFFREY RYAN | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 29057 | — | — | Stock Award(Grant) at price 0.00 per share. | DONOGHOE NICHOLAS | Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 48838 | — | — | Stock Award(Grant) at price 0.00 per share. | REENTS SCOTT T. | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 33518 | — | — | Stock Award(Grant) at price 0.00 per share. | SIATIS PERRY C. | General Counsel | — | 2026-02-18 00:00:00 | D |
| 6 | 18137 | — | — | Stock Award(Grant) at price 0.00 per share. | THAKKAR ROOPAL | Officer | — | 2026-02-18 00:00:00 | D |
| 7 | 6071 | — | — | Stock Award(Grant) at price 0.00 per share. | PURDUE DAVID R. | Officer | — | 2026-02-18 00:00:00 | D |
| 8 | 2460 | — | — | Stock Award(Grant) at price 0.00 per share. | CRUM DEMETRIS D | Officer | — | 2026-02-18 00:00:00 | D |
| 9 | 42370 | 8407055 | — | Sale at price 198.42 per share. | SALEKI-GERHARDT AZITA | Chief Operating Officer | — | 2025-08-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -583.38M | -203.28M | -102.25M | -5.66M |
| TaxRateForCalcs | 0.21 | 0.22 | 0.12 | 0.11 |
| NormalizedEBITDA | 17.69B | 18.10B | 25.02B | 23.98B |
| TotalUnusualItems | -2.78B | -924.00M | -845.00M | -51.00M |
| TotalUnusualItemsExcludingGoodwill | -2.78B | -924.00M | -845.00M | -51.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 4.28B | 4.86B | 11.84B | 11.54B |
| ReconciledDepreciation | 8.39B | 8.70B | 8.47B | 8.52B |
| ReconciledCostOfRevenue | 16.90B | 20.41B | 17.41B | 17.45B |
| EBITDA | 14.91B | 17.17B | 24.17B | 23.93B |
| EBIT | 6.52B | 8.47B | 15.71B | 15.41B |
| NetInterestIncome | -2.16B | -1.68B | -2.04B | -2.38B |
| InterestExpense | 2.81B | 2.22B | 2.23B | 2.42B |
| InterestIncome | 648.00M | 540.00M | 186.00M | 39.00M |
| NormalizedIncome | 6.47B | 5.58B | 12.58B | 11.59B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 4.28B | 4.86B | 11.84B | 11.54B |
| TotalExpenses | 44.44B | 40.78B | 39.24B | 38.27B |
| TotalOperatingIncomeAsReported | 9.14B | 12.76B | 18.12B | 17.92B |
| DilutedAverageShares | 1.77B | 1.77B | 1.77B | 1.78B |
| BasicAverageShares | 1.77B | 1.77B | 1.77B | 1.77B |
| DilutedEPS | 2.36 | 2.39 | 2.72 | 6.63 |
| BasicEPS | 2.39 | 2.42 | 2.75 | 6.69 |
| DilutedNIAvailtoComStockholders | 4.24B | 4.82B | 11.78B | 11.47B |
| NetIncomeCommonStockholders | 4.24B | 4.82B | 11.78B | 11.47B |
| OtherunderPreferredStockDividend | 40.00M | 43.00M | 54.00M | 74.00M |
| NetIncome | 4.28B | 4.86B | 11.84B | 11.54B |
| MinorityInterests | -8.00M | -10.00M | -9.00M | -7.00M |
| NetIncomeIncludingNoncontrollingInterests | 4.29B | 4.87B | 11.85B | 11.55B |
| NetIncomeContinuousOperations | 4.29B | 4.87B | 11.85B | 11.55B |
| TaxProvision | -570.00M | 1.38B | 1.63B | 1.44B |
| PretaxIncome | 3.72B | 6.25B | 13.48B | 12.99B |
| OtherIncomeExpense | -6.02B | -5.60B | -3.29B | -2.55B |
| OtherNonOperatingIncomeExpenses | -3.24B | -4.68B | -2.45B | -2.50B |
| SpecialIncomeCharges | -2.76B | -778.00M | -697.00M | -1.12B |
| OtherSpecialCharges | 2.76B | 778.00M | 697.00M | 1.12B |
| GainOnSaleOfSecurity | -21.00M | -146.00M | -148.00M | -51.00M |
| NetNonOperatingInterestIncomeExpense | -2.16B | -1.68B | -2.04B | -2.38B |
| InterestExpenseNonOperating | 2.81B | 2.22B | 2.23B | 2.42B |
| InterestIncomeNonOperating | 648.00M | 540.00M | 186.00M | 39.00M |
| OperatingIncome | 11.89B | 13.54B | 18.81B | 17.92B |
| OperatingExpense | 27.54B | 20.37B | 21.83B | 20.83B |
| OtherOperatingExpenses | -7.00M | -179.00M | 56.00M | 432.00M |
| ResearchAndDevelopment | 12.79B | 7.67B | 6.51B | 8.05B |
| SellingGeneralAndAdministration | 14.75B | 12.87B | 15.26B | 12.35B |
| GrossProfit | 39.43B | 33.90B | 40.64B | 38.75B |
| CostOfRevenue | 16.90B | 20.41B | 17.41B | 17.45B |
| TotalRevenue | 56.33B | 54.32B | 58.05B | 56.20B |
| OperatingRevenue | 56.33B | 54.32B | 58.05B | 56.20B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 66.34M | 57.11M | 44.59M | 34.86M |
| OrdinarySharesNumber | 1.77B | 1.77B | 1.77B | 1.77B |
| ShareIssued | 1.83B | 1.82B | 1.81B | 1.80B |
| NetDebt | 61.62B | 46.57B | 54.07B | 66.94B |
| TotalDebt | 67.14B | 59.38B | 63.27B | 76.68B |
| TangibleBookValue | -91.70B | -77.54B | -82.34B | -92.92B |
| InvestedCapital | 70.47B | 69.75B | 80.53B | 92.09B |
| WorkingCapital | -13.17B | -4.84B | -1.07B | -7.27B |
| NetTangibleAssets | -91.70B | -77.54B | -82.34B | -92.92B |
| CommonStockEquity | 3.33B | 10.36B | 17.25B | 15.41B |
| TotalCapitalization | 63.66B | 62.55B | 76.39B | 79.60B |
| TotalEquityGrossMinorityInterest | 3.36B | 10.40B | 17.29B | 15.44B |
| MinorityInterest | 39.00M | 37.00M | 33.00M | 28.00M |
| StockholdersEquity | 3.33B | 10.36B | 17.25B | 15.41B |
| GainsLossesNotAffectingRetainedEarnings | -1.93B | -2.31B | -2.20B | -2.90B |
| OtherEquityAdjustments | -1.93B | -2.31B | -2.20B | -2.90B |
| TreasuryStock | 8.20B | 6.53B | 4.59B | 3.14B |
| RetainedEarnings | -7.90B | -1.00B | 4.78B | 3.13B |
| AdditionalPaidInCapital | 21.33B | 20.18B | 19.25B | 18.30B |
| CapitalStock | 18.00M | 18.00M | 18.00M | 18.00M |
| CommonStock | 18.00M | 18.00M | 18.00M | 18.00M |
| TotalLiabilitiesNetMinorityInterest | 131.80B | 124.31B | 121.52B | 131.09B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 93.05B | 86.47B | 91.98B | 95.90B |
| OtherNonCurrentLiabilities | 27.63B | 28.61B | 26.03B | 22.11B |
| EmployeeBenefits | 1.23B | 1.54B | 1.64B | 3.15B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.23B | 1.54B | 1.64B | 3.15B |
| TradeandOtherPayablesNonCurrent | 1.26B | 2.18B | 2.98B | 3.44B |
| NonCurrentDeferredLiabilities | 2.58B | 1.95B | 2.19B | 3.01B |
| NonCurrentDeferredTaxesLiabilities | 2.58B | 1.95B | 2.19B | 3.01B |
| LongTermDebtAndCapitalLeaseObligation | 60.34B | 52.19B | 59.13B | 64.19B |
| LongTermDebt | 60.34B | 52.19B | 59.13B | 64.19B |
| CurrentLiabilities | 38.75B | 37.84B | 29.54B | 35.19B |
| CurrentDeferredLiabilities | 14.30B | 13.63B | 10.72B | 8.25B |
| CurrentDeferredRevenue | 14.30B | 13.63B | 10.72B | 8.25B |
| CurrentDebtAndCapitalLeaseObligation | 6.80B | 7.19B | 4.14B | 12.49B |
| CurrentDebt | 6.80B | 7.19B | 4.14B | 12.49B |
| PayablesAndAccruedExpenses | 17.64B | 17.02B | 14.69B | 14.45B |
| CurrentAccruedExpenses | 11.76B | 10.55B | 9.07B | 9.02B |
| Payables | 5.88B | 6.47B | 5.61B | 5.42B |
| DividendsPayable | 2.94B | 2.78B | 2.68B | 2.54B |
| AccountsPayable | 2.94B | 3.69B | 2.93B | 2.88B |
| TotalAssets | 135.16B | 134.71B | 138.81B | 146.53B |
| TotalNonCurrentAssets | 109.58B | 101.71B | 110.34B | 118.60B |
| OtherNonCurrentAssets | 9.14B | 8.51B | 5.57B | 4.88B |
| InvestmentsAndAdvances | 279.00M | 304.00M | 241.00M | 277.00M |
| GoodwillAndOtherIntangibleAssets | 95.02B | 87.90B | 99.59B | 108.33B |
| OtherIntangibleAssets | 60.07B | 55.61B | 67.44B | 75.95B |
| Goodwill | 34.96B | 32.29B | 32.16B | 32.38B |
| NetPPE | 5.13B | 4.99B | 4.93B | 5.11B |
| AccumulatedDepreciation | -7.13B | -6.65B | -6.05B | -5.62B |
| GrossPPE | 12.27B | 11.63B | 10.99B | 10.73B |
| ConstructionInProgress | 1.09B | 1.07B | 856.00M | 799.00M |
| OtherProperties | 8.00B | 7.45B | ||
| MachineryFurnitureEquipment | 8.00B | 7.45B | 7.11B | 6.85B |
| BuildingsAndImprovements | 2.90B | 2.83B | 2.74B | 2.79B |
| LandAndImprovements | 284.00M | 286.00M | 286.00M | 287.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.58B | 33.00B | 28.46B | 27.93B |
| OtherCurrentAssets | 4.93B | 4.93B | 4.40B | 4.99B |
| PrepaidAssets | 4.99B | |||
| Inventory | 4.18B | 4.10B | 3.58B | 3.13B |
| FinishedGoods | 1.17B | 1.36B | 1.16B | 932.00M |
| WorkInProcess | 1.95B | 1.64B | 1.42B | 1.19B |
| RawMaterials | 1.06B | 1.10B | 1.00B | 1.00B |
| Receivables | 10.92B | 11.15B | 11.25B | 9.98B |
| AccountsReceivable | 10.92B | 11.15B | 11.25B | 9.98B |
| CashCashEquivalentsAndShortTermInvestments | 5.55B | 12.82B | 9.23B | 9.83B |
| OtherShortTermInvestments | 31.00M | 2.00M | 28.00M | 84.00M |
| CashAndCashEquivalents | 5.52B | 12.81B | 9.20B | 9.75B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 17.83B | 22.06B | 24.25B | 21.99B |
| RepurchaseOfCapitalStock | -1.71B | -1.97B | -1.49B | -934.00M |
| RepaymentOfDebt | -14.62B | -4.15B | -14.43B | -9.41B |
| IssuanceOfDebt | 21.97B | 0.00 | 2.00B | 1.00B |
| CapitalExpenditure | -974.00M | -777.00M | -695.00M | -787.00M |
| InterestPaidSupplementalData | 2.81B | 2.47B | 2.55B | 2.71B |
| IncomeTaxPaidSupplementalData | 4.06B | 4.70B | 2.99B | 3.65B |
| EndCashPosition | 5.52B | 12.81B | 9.20B | 9.75B |
| BeginningCashPosition | 12.81B | 9.20B | 9.75B | 8.45B |
| EffectOfExchangeRateChanges | -65.00M | 5.00M | -62.00M | -97.00M |
| ChangesInCash | -7.22B | 3.61B | -483.00M | 1.39B |
| FinancingCashFlow | -5.21B | -17.22B | -24.80B | -19.04B |
| CashFlowFromContinuingFinancingActivities | -5.21B | -17.22B | -24.80B | -19.04B |
| NetOtherFinancingCharges | -42.00M | -742.00M | -1.10B | -674.00M |
| ProceedsFromStockOptionExercised | 214.00M | 180.00M | 262.00M | 244.00M |
| CashDividendsPaid | -11.03B | -10.54B | -10.04B | -9.26B |
| CommonStockDividendPaid | -11.03B | -10.54B | -10.04B | -9.26B |
| NetCommonStockIssuance | -1.71B | -1.97B | -1.49B | -934.00M |
| CommonStockPayments | -1.71B | -1.97B | -1.49B | -934.00M |
| NetIssuancePaymentsOfDebt | 7.35B | -4.15B | -12.43B | -8.41B |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | 0.00 |
| ShortTermDebtPayments | -5.01B | 0.00 | 0.00 | 0.00 |
| ShortTermDebtIssuance | 5.01B | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 7.35B | -4.15B | -12.43B | -8.41B |
| LongTermDebtPayments | -9.61B | -4.15B | -14.43B | -9.41B |
| LongTermDebtIssuance | 16.96B | 0.00 | 2.00B | 1.00B |
| InvestingCashFlow | -20.82B | -2.01B | -623.00M | -2.34B |
| CashFlowFromContinuingInvestingActivities | -20.82B | -2.01B | -623.00M | -2.34B |
| NetOtherInvestingChanges | 189.00M | 13.00M | 774.00M | 366.00M |
| NetInvestmentPurchaseAndSale | 482.00M | -22.00M | 92.00M | -21.00M |
| SaleOfInvestment | 555.00M | 55.00M | 1.53B | 98.00M |
| PurchaseOfInvestment | -73.00M | -77.00M | -1.44B | -119.00M |
| NetBusinessPurchaseAndSale | -20.52B | -1.22B | -794.00M | -1.90B |
| PurchaseOfBusiness | -20.52B | -1.22B | -794.00M | -1.90B |
| NetPPEPurchaseAndSale | -974.00M | -777.00M | -695.00M | -787.00M |
| PurchaseOfPPE | -974.00M | -777.00M | -695.00M | -787.00M |
| OperatingCashFlow | 18.81B | 22.84B | 24.94B | 22.78B |
| CashFlowFromContinuingOperatingActivities | 18.81B | 22.84B | 24.94B | 22.78B |
| ChangeInWorkingCapital | -2.78B | 2.81B | -94.00M | -1.23B |
| ChangeInOtherWorkingCapital | -3.21B | -488.00M | 542.00M | -1.29B |
| ChangeInPayablesAndAccruedExpense | 177.00M | 3.84B | 1.77B | 1.72B |
| ChangeInPayable | 177.00M | 3.84B | 1.77B | 1.72B |
| ChangeInAccountPayable | 177.00M | 3.84B | 1.77B | 1.72B |
| ChangeInPrepaidAssets | 361.00M | -188.00M | -264.00M | -197.00M |
| ChangeInInventory | -319.00M | -417.00M | -686.00M | -142.00M |
| ChangeInReceivables | 207.00M | 66.00M | -1.46B | -1.32B |
| ChangesInAccountReceivables | 207.00M | 66.00M | -1.46B | -1.32B |
| OtherNonCashItems | 4.47B | 4.81B | 3.14B | 4.00B |
| StockBasedCompensation | 911.00M | 747.00M | 671.00M | 692.00M |
| ProvisionandWriteOffofAssets | 508.00M | -443.00M | 2.24B | 163.00M |
| AssetImpairmentCharge | 4.48B | 4.23B | 770.00M | 50.00M |
| DeferredTax | -1.45B | -2.89B | -1.93B | -898.00M |
| DeferredIncomeTax | -1.45B | -2.89B | -1.93B | -898.00M |
| DepreciationAmortizationDepletion | 8.39B | 8.70B | 8.47B | 8.52B |
| DepreciationAndAmortization | 8.39B | 8.70B | 8.47B | 8.52B |
| AmortizationCashFlow | 7.62B | 7.95B | 7.69B | 7.72B |
| AmortizationOfIntangibles | 7.62B | 7.95B | 7.69B | 7.72B |
| Depreciation | 764.00M | 752.00M | 778.00M | 803.00M |
| OperatingGainsLosses | -172.00M | -68.00M | ||
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -172.00M | -68.00M |
| NetIncomeFromContinuingOperations | 4.29B | 4.87B | 11.85B | 11.55B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABBV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|